<PAGE>
Securities and Exchange Commission
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
January 24, 2000
----------------
IMX PHARMACEUTICALS, INC.
--------------------------------------------------
(Exact name of Registrant as specified in its charter)
Commission File Number 000-30294
---------
Utah 87-0394290
- ---- ----------
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
2295 Corporate Boulevard, Suite 131, Boca Raton, Florida 33431
--------------------------------------------------------------
(Address of Principal Executive Offices)
561-998-5660
------------
(Registrant's Telephone number, including area code)
<PAGE>
ITEM 4. Changes in Registrant's Certifying Accountant.
- ------- ----------------------------------------------
On January 24, 2000, IMX Pharmaceuticals, Inc. (the "Registrant"),
dismissed BDO Seidman, LLP (the "Former Accountants") as the Registrant's
certifying accountants. The audit committee of the Registrant recommended
dismissal to the Registrant's Board of Directors, which dismissed the Former
Accountants.
During the past two (2) fiscal years, the financial statements of the
Registrant did not contain an adverse opinion or disclaimer of opinion, and were
not qualified or modified as to uncertainty, audit scope or accounting
principles.
During the past two (2) fiscal years and subsequent interim periods,
there were no disagreements with the Former Accountants as to auditing
principles or practices, financial statements and disclosure or auditing scope
or procedure of the type required to be disclosed by Reg. SK 304(a)(1)(iv). In
addition, there were no "reportable events" of the type required to be disclosed
by Reg. SK 304(a)(1)(v). A letter from the Former Accountants with regard to the
above is filed herewith.
The Registrant has retained the firm of Berenfeld, Spritzer, Shechter &
Sheer (the "New Accountants") on January 24, 2000. During the two (2) most
recent fiscal years and subsequent interim periods, the New Accountants were not
consulted regarding: (i) the application of accounting principles to a specific
transaction, (ii) the type of audit opinion to be rendered with regard to the
Registrant's financial statements or (iii) any disagreements or reportable
events as such terms are defined in Reg. SK 304(a)(1)(iv) and Regulation SK 304
(a)(1)(v), respectively.
ITEM 7. Financial Statements and Exhibits.
- ------- ----------------------------------
Exhibit 16.1. Letter dated January 26, 2000 from the Former
Accountants.
2
<PAGE>
SIGNATURES
----------
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant duly caused this report to be signed on its behalf by the
undersigned hereto duly authorized.
IMX PHARMACEUTICALS, INC.
By: /s/ William A. Forster
----------------------
William A. Forster, President
Dated: January 26, 2000
3
<PAGE>
EXHIBIT 16.1
[LETTERHEAD OF BDO SEIDMAN, LLP]
561-688-1600
January 26, 2000
Securities and Exchange Commission
450 5th Street N.W.
Washington, D.C. 20549
Gentlemen:
We have been furnished with a copy of the response to Item 4 of Form 8-K for the
event that occurred on January 24, 2000 to be filed by our former client, the
IMX Pharmaceuticals, Inc. We agree with the statements made in response to that
Item insofar as they relate to our Firm.
Very truly yours,
/s/ BDO Seidman, LLP
- --------------------
BDO Seidman, LLP
4
